Efficacy of interventions targeted at physician prescribers of opioids for chronic non-cancer pain: an overview of systematic reviews.
Opioid
Overview
Prescribing
Systematic review
Umbrella review
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
20 Feb 2024
20 Feb 2024
Historique:
received:
16
06
2023
accepted:
07
02
2024
medline:
21
2
2024
pubmed:
21
2
2024
entrez:
20
2
2024
Statut:
epublish
Résumé
To combat the opioid crisis, interventions targeting the opioid prescribing behaviour of physicians involved in the management of patients with chronic non-cancer pain (CNCP) have been introduced in clinical settings. An integrative synthesis of systematic review evidence is required to better understand the effects of these interventions. Our objective was to synthesize the systematic review evidence on the effect of interventions targeting the behaviours of physician opioid prescribers for CNCP among adults on patient and population health and prescriber behaviour. We searched MEDLINE, Embase, and PsycInfo via Ovid; the Cochrane Database of Systematic Reviews; and Epistemonikos. We included systematic reviews that evaluate any type of intervention aimed at impacting opioid prescriber behaviour for adult CNCP in an outpatient setting. We identified three full texts for our review that contained 68 unique primary studies. The main interventions we evaluated were structured prescriber education (one review) and prescription drug monitoring programmes (PDMPs) (two reviews). Due to the paucity of data available, we could not determine with certainty that education interventions improved outcomes in deprescribing. There is some evidence that PDMPs decrease the number of adverse opioid-related events, increase communication among healthcare workers and patients, modify healthcare practitioners' approach towards their opioid prescribed patients, and offer more chances for education and counselling. Our overview explores the possibility of PDMPs as an opioid deprescribing intervention and highlights the need for more high-quality primary research on this topic.
Sections du résumé
BACKGROUND
BACKGROUND
To combat the opioid crisis, interventions targeting the opioid prescribing behaviour of physicians involved in the management of patients with chronic non-cancer pain (CNCP) have been introduced in clinical settings. An integrative synthesis of systematic review evidence is required to better understand the effects of these interventions. Our objective was to synthesize the systematic review evidence on the effect of interventions targeting the behaviours of physician opioid prescribers for CNCP among adults on patient and population health and prescriber behaviour.
METHODS
METHODS
We searched MEDLINE, Embase, and PsycInfo via Ovid; the Cochrane Database of Systematic Reviews; and Epistemonikos. We included systematic reviews that evaluate any type of intervention aimed at impacting opioid prescriber behaviour for adult CNCP in an outpatient setting.
RESULTS
RESULTS
We identified three full texts for our review that contained 68 unique primary studies. The main interventions we evaluated were structured prescriber education (one review) and prescription drug monitoring programmes (PDMPs) (two reviews). Due to the paucity of data available, we could not determine with certainty that education interventions improved outcomes in deprescribing. There is some evidence that PDMPs decrease the number of adverse opioid-related events, increase communication among healthcare workers and patients, modify healthcare practitioners' approach towards their opioid prescribed patients, and offer more chances for education and counselling.
CONCLUSIONS
CONCLUSIONS
Our overview explores the possibility of PDMPs as an opioid deprescribing intervention and highlights the need for more high-quality primary research on this topic.
Identifiants
pubmed: 38378544
doi: 10.1186/s12916-024-03287-1
pii: 10.1186/s12916-024-03287-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
76Informations de copyright
© 2024. Crown.
Références
Harper S, Riddell CA, King NB. Declining Life Expectancy in the United States: Missing the Trees for the Forest. Annu Rev Public Health. 2021;42:381–403.
pubmed: 33326297
doi: 10.1146/annurev-publhealth-082619-104231
Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011;1:a006841.
pubmed: 22229120
pmcid: 3234451
doi: 10.1101/cshperspect.a006841
DeWeerdt S. Tracing the US opioid crisis to its roots. Nature. 2019;573:S10–2.
pubmed: 31511672
doi: 10.1038/d41586-019-02686-2
The L. A time of crisis for the opioid epidemic in the USA. Lancet. 2021;398:277.
doi: 10.1016/S0140-6736(21)01653-6
Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and Treatment of Opioid Misuse and Addiction: A Review. JAMA Psychiat. 2019;76:208–16.
doi: 10.1001/jamapsychiatry.2018.3126
Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA. 2018;319:872–82.
pubmed: 29509867
pmcid: 5885909
doi: 10.1001/jama.2018.0899
Jones CMP, Day RO, Koes BW, et al. Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial. Lancet. 2023;402:304–12.
pubmed: 37392748
doi: 10.1016/S0140-6736(23)00404-X
Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep. 2022;71:1–95.
pubmed: 36327391
pmcid: 9639433
doi: 10.15585/mmwr.rr7103a1
Lee B, Zhao W, Yang K-C, Ahn Y-Y, Perry BL. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007–2018. JAMA Network Open. 2021;4:e2036687-e.
doi: 10.1001/jamanetworkopen.2020.36687
Buchmueller TC, Carey C. The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare. Am Econ J Econ Pol. 2018;10:77–112.
doi: 10.1257/pol.20160094
Pauly NJ, Slavova S, Delcher C, Freeman PR, Talbert J. Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings. Drug Alcohol Depend. 2018;184:26–32.
pubmed: 29402676
pmcid: 5854200
doi: 10.1016/j.drugalcdep.2017.12.002
Paulozzi LJ, Kilbourne EM, Desai HA. Prescription Drug Monitoring Programs and Death Rates from Drug Overdose. Pain Med. 2011;12:747–54.
pubmed: 21332934
doi: 10.1111/j.1526-4637.2011.01062.x
Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. JAMA. 2016;315:1624–45.
pubmed: 26977696
pmcid: 6390846
doi: 10.1001/jama.2016.1464
Jason WB, Samantha C, David NJ, et al. Guideline for opioid therapy and chronic noncancer pain. Can Med Assoc J. 2017;189:E659.
doi: 10.1503/cmaj.170363
Nadeau SE, Lawhern RA. Management of chronic non-cancer pain: a framework. Pain Manag. 2022;12:751–77.
pubmed: 35642546
doi: 10.2217/pmt-2022-0017
Volkow N, Benveniste H, McLellan AT. Use and Misuse of Opioids in Chronic Pain. Annu Rev Med. 2018;69:451–65.
pubmed: 29029586
doi: 10.1146/annurev-med-011817-044739
Pollock M, Fernandes RM, Becker LA, Pieper D, Hartling L. Chapter V: overviews of reviews. Cochrane handbook for systematic reviews of interventions version 2020;6.
Pollock M, Fernandes RM, Becker LA, Featherstone R, Hartling L. What guidance is available for researchers conducting overviews of reviews of healthcare interventions? A scoping review and qualitative metasummary. Syst Rev. 2016;5:190.
pubmed: 27842604
pmcid: 5109841
doi: 10.1186/s13643-016-0367-5
Interventions for physician prescribers of opioids for chronic non-cancer pain: an overview of systematic reviews. 2022. at https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=156815 .)
McKeown S, Mir ZM. Considerations for conducting systematic reviews: evaluating the performance of different methods for de-duplicating references. Syst Rev. 2021;10:38.
pubmed: 33485394
pmcid: 7827976
doi: 10.1186/s13643-021-01583-y
Pieper D, Antoine SL, Mathes T, Neugebauer EA, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014;67:368–75.
pubmed: 24581293
doi: 10.1016/j.jclinepi.2013.11.007
Whiting P, Savović J, Higgins JP, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225–34.
pubmed: 26092286
pmcid: 4687950
doi: 10.1016/j.jclinepi.2015.06.005
Picco L, Lam T, Haines S, Nielsen S. How prescription drug monitoring programs influence clinical decision-making: A mixed methods systematic review and meta-analysis. Drug Alcohol Depend. 2021;228:109090.
pubmed: 34600255
doi: 10.1016/j.drugalcdep.2021.109090
Puac-Polanco V, Chihuri S, Fink DS, Cerdá M, Keyes KM, Li G. Prescription Drug Monitoring Programs and Prescription Opioid-Related Outcomes in the United States. Epidemiol Rev. 2020;42:134–53.
pubmed: 32242239
pmcid: 7947593
doi: 10.1093/epirev/mxaa002
Mathieson S, Maher CG, Ferreira GE, et al. Deprescribing Opioids in Chronic Non-cancer Pain: Systematic Review of Randomised Trials. Drugs. 2020;80:1563–76.
pubmed: 32737739
doi: 10.1007/s40265-020-01368-y
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
pubmed: 22008217
pmcid: 3196245
doi: 10.1136/bmj.d5928
Hong QN, Gonzalez-Reyes A, Pluye P. Improving the usefulness of a tool for appraising the quality of qualitative, quantitative and mixed methods studies, the Mixed Methods Appraisal Tool (MMAT). J Eval Clin Pract. 2018;24:459–67.
pubmed: 29464873
doi: 10.1111/jep.12884
Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45.
pubmed: 24690082
pmcid: 4021422
doi: 10.1186/1471-2288-14-45
Kurita GP, Højsted J, Sjøgren P. Tapering off long-term opioid therapy in chronic non-cancer pain patients: A randomized clinical trial. Eur J Pain. 2018. https://doi.org/10.1002/ejp.1241 . Epub ahead of print.
Blondell RD, Ashrafioun L, Dambra CM, Foschio EM, Zielinski AL, Salcedo DM. A Clinical Trial Comparing Tapering Doses of Buprenorphine with Steady Doses for Chronic Pain and Co-existent Opioid Addiction. J Addict Med. 2010;4:140–6.
pubmed: 20959867
pmcid: 2931595
doi: 10.1097/ADM.0b013e3181ba895d
Garland EL, Manusov EG, Froeliger B, Kelly A, Williams JM, Howard MO. Mindfulness-oriented recovery enhancement for chronic pain and prescription opioid misuse: results from an early-stage randomized controlled trial. J Consult Clin Psychol. 2014;82:448–59.
pubmed: 24491075
pmcid: 4076008
doi: 10.1037/a0035798
Hooten WM, Warner DO. Varenicline for opioid withdrawal in patients with chronic pain: a randomized, single-blinded, placebo controlled pilot trial. Addict Behav. 2015;42:69–72.
pubmed: 25462656
doi: 10.1016/j.addbeh.2014.11.007
Naylor MR, Naud S, Keefe FJ, Helzer JE. Therapeutic Interactive Voice Response (TIVR) to reduce analgesic medication use for chronic pain management. J pain. 2010;11:1410–9.
pubmed: 20620119
pmcid: 3045626
doi: 10.1016/j.jpain.2010.03.019
Ringwalt C, Shanahan M, Wodarski S, et al. A Randomized Controlled Trial of an Emergency Department Intervention for Patients with Chronic Noncancer Pain. J Emerg Med. 2015;49:974–83.
pubmed: 26423915
pmcid: 6684210
doi: 10.1016/j.jemermed.2015.03.004
Sullivan MD, Turner JA, DiLodovico C, D’Appollonio A, Stephens K, Chan YF. Prescription Opioid Taper Support for Outpatients With Chronic Pain: A Randomized Controlled Trial. The journal of pain : official journal of the American Pain Society. 2017;18:308–18.
doi: 10.1016/j.jpain.2016.11.003
Webster L, Gruener D, Kirby T, Xiang Q, Tzanis E, Finn A. Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine. Pain medicine (Malden, Mass). 2016;17:899–907.
pubmed: 26917621
Zgierska AE, Burzinski CA, Cox J, et al. Mindfulness Meditation and Cognitive Behavioral Therapy Intervention Reduces Pain Severity and Sensitivity in Opioid-Treated Chronic Low Back Pain: Pilot Findings from a Randomized Controlled Trial. Pain med (Malden, Mass). 2016;17:1865–81.
doi: 10.1093/pm/pnw006
Liebschutz JM, Xuan Z, Shanahan CW, et al. Improving Adherence to Long-term Opioid Therapy Guidelines to Reduce Opioid Misuse in Primary Care: A Cluster-Randomized Clinical Trial. JAMA Intern Med. 2017;177:1265–72.
pubmed: 28715535
pmcid: 5710574
doi: 10.1001/jamainternmed.2017.2468
Trudeau KJ, Hildebrand C, Garg P, Chiauzzi E, Zacharoff KL. A Randomized Controlled Trial of the Effects of Online Pain Management Education on Primary Care Providers. Pain Med. 2017;18:680–92.
pubmed: 28034967
Lasser KE, Shanahan C, Parker V, et al. A Multicomponent Intervention to Improve Primary Care Provider Adherence to Chronic Opioid Therapy Guidelines and Reduce Opioid Misuse: A Cluster Randomized Controlled Trial Protocol. J Subst Abuse Treat. 2016;60:101–9.
pubmed: 26256769
doi: 10.1016/j.jsat.2015.06.018
Barrett K, Watson A. Physician Perspectives on a Pilot Prescription Monitoring Program. J Pain Palliat Care Pharmacother. 2005;19:5–13.
pubmed: 16219606
doi: 10.1080/J354v19n03_03
Feldman L, Williams KS, Coates J, Knox M. Awareness and utilization of a prescription monitoring program among physicians. J Pain Palliat Care Pharmacother. 2011;25:313–7.
pubmed: 21936637
doi: 10.3109/15360288.2011.606292
Perrone J, DeRoos FJ, Nelson LS. Prescribing practices, knowledge, and use of prescription drug monitoring programs (PDMP) by a national sample of medical toxicologists, 2012. J Med Toxicol. 2012;8:341–52.
pubmed: 22895794
pmcid: 3550254
doi: 10.1007/s13181-012-0250-2
Gershman JA, Gershman JA, Fass AD, Popovici I. Evaluation of Florida physicians’ knowledge and attitudes toward accessing the state prescription drug monitoring program as a prescribing tool. Pain med (Malden, Mass). 2014;15:2013–9.
doi: 10.1111/pme.12476
Rittenhouse R, Wei F, Robertson D, Ryan K. Utilization of the Arkansas Prescription Monitoring Program to Combat Prescription Drug Abuse. Prev Med Rep. 2015;2:524–8.
pubmed: 26191489
pmcid: 4502438
doi: 10.1016/j.pmedr.2015.06.006
Rutkow L, Turner L, Lucas E, Hwang C, Alexander GC. Most Primary Care Physicians Are Aware Of Prescription Drug Monitoring Programs, But Many Find The Data Difficult To Access. Health Aff. 2015;34:484–92.
doi: 10.1377/hlthaff.2014.1085
McCauley JL, Leite RS, Melvin CL, Fillingim RB, Brady KT. Dental opioid prescribing practices and risk mitigation strategy implementation: Identification of potential targets for provider-level intervention. Substance abuse. 2016;37:9–14.
pubmed: 26675303
doi: 10.1080/08897077.2015.1127870
Hernandez-Meier JL, Muscott R, Zosel A. The Use of a Statewide Prescription Drug Monitoring Program by Emergency Department Physicians. WMJ. 2017;116:64–8.
pubmed: 29323819
Lin DH, Lucas E, Murimi IB, et al. Physician attitudes and experiences with Maryland’s prescription drug monitoring program (PDMP). Addiction (Abingdon, England). 2017;112:311–9.
pubmed: 27658522
doi: 10.1111/add.13620
McCauley JL, Leite RS, Gordan VV, et al. Opioid prescribing and risk mitigation implementation in the management of acute pain: Results from The National Dental Practice-Based Research Network. J Am Dent Assoc. 2018;149:353–62.
pubmed: 29550022
pmcid: 5924603
doi: 10.1016/j.adaj.2017.11.031
Ovadia SA, Garcia O Jr, Thaller SR. Changes in Opioid Prescribing Patterns: A Survey of the Florida Society of Plastic Surgeons. Ann Plast Surg. 2020;85:e54–8.
pubmed: 32149844
doi: 10.1097/SAP.0000000000002318
Goodin A, Bae J, Delcher C, Brown J, Roussos-Ross D. Obstetrician-gynecologist perceptions and utilization of prescription drug monitoring programs: A survey study. Medicine (Baltimore). 2021;100:e24268.
pubmed: 33429837
doi: 10.1097/MD.0000000000024268
Al-Astal AY, Sodhi K, Lakhani HV. Optimization of Prescription Drug Monitoring Program to Overcome Opioid Epidemic in West Virginia. Cureus. 2022;14:e22434.
pubmed: 35371719
pmcid: 8941824
Baehren DF, Marco CA, Droz DE, Sinha S, Callan EM, Akpunonu P. A statewide prescription monitoring program affects emergency department prescribing behaviors. Ann Emerg Med. 2010;56:19-23.e1-3.
pubmed: 20045578
doi: 10.1016/j.annemergmed.2009.12.011
Weiner SG, Griggs CA, Mitchell PM, et al. Clinician impression versus prescription drug monitoring program criteria in the assessment of drug-seeking behavior in the emergency department. Ann Emerg Med. 2013;62:281–9.
pubmed: 23849618
doi: 10.1016/j.annemergmed.2013.05.025
Nam YH, Shea DG, Shi Y, Moran JR. State prescription drug monitoring programs and fatal drug overdoses. Am J Manag Care. 2017;23:297–303.
pubmed: 28738683
Barrett K, Watson A. Physician perspectives on a pilot prescription monitoring program. J Pain Palliat Care Pharmacother. 2005;19:5–13.
pubmed: 16219606
doi: 10.1080/J354v19n03_03
Irvine JM, Hallvik SE, Hildebran C, Marino M, Beran T, Deyo RA. Who uses a prescription drug monitoring program and how? Insights from a statewide survey of Oregon clinicians. J Pain. 2014;15:747–55.
pubmed: 24787089
pmcid: 4079731
doi: 10.1016/j.jpain.2014.04.003
Thomas CP, Kim M, Nikitin RV, Kreiner P, Clark TW, Carrow GM. Prescriber response to unsolicited prescription drug monitoring program reports in Massachusetts. Pharmacoepidemiol Drug Saf. 2014;23:950–7.
pubmed: 24920376
doi: 10.1002/pds.3666
Dowell D, Zhang K, Noonan RK, Hockenberry JM. Mandatory Provider Review And Pain Clinic Laws Reduce The Amounts Of Opioids Prescribed And Overdose Death Rates. Health Aff (Millwood). 2016;35:1876–83.
pubmed: 27702962
doi: 10.1377/hlthaff.2016.0448
Grecu AM, Dave DM, Saffer H. Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse. J Policy Anal Manage. 2019;38:181–209.
pubmed: 30572414
doi: 10.1002/pam.22098
Delcher C, Wagenaar AC, Goldberger BA, Cook RL, Maldonado-Molina MM. Abrupt decline in oxycodone-caused mortality after implementation of Florida’s Prescription Drug Monitoring Program. Drug Alcohol Depend. 2015;150:63–8.
pubmed: 25746236
doi: 10.1016/j.drugalcdep.2015.02.010
Phillips E, Gazmararian J. Implications of prescription drug monitoring and medical cannabis legislation on opioid overdose mortality. J Opioid Manag. 2017;13:229–39.
pubmed: 28953315
doi: 10.5055/jom.2017.0391
Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain medicine (Malden, Mass). 2011;12:747–54.
pubmed: 21332934
doi: 10.1111/j.1526-4637.2011.01062.x
Haffajee RL, Mello MM, Zhang F, Zaslavsky AM, Larochelle MR, Wharam JF. Four States With Robust Prescription Drug Monitoring Programs Reduced Opioid Dosages. Health affairs (Project Hope). 2018;37:964–74.
pubmed: 29863921
doi: 10.1377/hlthaff.2017.1321
D'Souza RS, Lang M, Eldrige JS. Prescription Drug Monitoring Program. 2023 Jun 20. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
Lin HC, Wang Z, Boyd C, Simoni-Wastila L, Buu A. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain. Addict Behav. 2018;76:348–54.
pubmed: 28898808
doi: 10.1016/j.addbeh.2017.08.032
Noble MC, Ingram V. 2020 Overdose Fatality Report - Kentucky Office of Drug Control Policy. rep. Commonwealth of Kentucky Justice & Public Safety Cabinet. 2020. p. 5–12.
Dowell D, Haegerich T, Chou R. No Shortcuts to Safer Opioid Prescribing. N Engl J Med. 2019;380:2285–7.
pubmed: 31018066
pmcid: 6573011
doi: 10.1056/NEJMp1904190
Incident Analysis Collaborating Parties. Canadian Incident Analysis Framework. Edmonton, AB: Canadian Patient Safety Institute; 2012. Incident Analysis Collaborating Parties are Canadian Patient Safety Institute (CPSI), Institute for Safe Medication Practices Canada, Saskatchewan Health, Patients for Patient Safety Canada (a patient-led program of CPSI), Paula Beard, Carolyn E. Hoffman and Micheline Ste-Marie.